Antibiotics start-up company Auspherix launches
03 December, 2013Today saw the launch of early-stage anti-infectives company Auspherix, which will develop novel antibiotics to treat resistant bacterial disease. The company has received $1 million in financing from the Medical Research Commercialisation Fund (MRCF).
ResMed expands in EU with new M&A
03 December, 2013 by Dylan Bushell-EmblingResMed (ASX:RMD) has acquired a Prague sleep breathing device distributor, giving it a dedicated presence in the markets of the Czech Republic and Slovakia.
Cook's MD named health and pharma executive of the year
03 December, 2013Managing director of Cook Australia and AusBiotech member Barry Thomas has been named the 2013 'Health and Pharmaceutical Executive of the Year' by The CEO Magazine. The Executive of the Year Awards, held last week in Sydney, recognise individual excellence of high-level executives and the contributions they have made to their companies.
Bioniche to delist from ASX
02 December, 2013 by Dylan Bushell-EmblingDual-listed Bioniche (ASX:BNC) has entered negotiations to sell off its animal health division and plans to withdraw from trading on the ASX in 1H14.
BRW lists Planet Innovation as Australia's most innovative company
02 December, 2013BRW has released its second list of Australia's Most Innovative Companies. Topping the list for 2013 is biotech company Planet Innovation, which last year ranked eighth on the list.
Biotron's BIT225 could work in all HCV strains
28 November, 2013 by Dylan Bushell-EmblingIndependent research published in a scientific journal suggests that Biotron's (ASX:BIT) BIT225 drug candidate shows activity in all six major strains of hepatitis C.
Biotech Christmas celebrations kick off next week
28 November, 2013State-by-state Christmas celebrations start next week, with Western Australia the first to host AusBiotech's free Christmas event as their final networking event of 2013. The AusBiotech branch committee in each state is pleased to invite AusBiotech members to the end-of-year celebration in thanks for their support throughout 2013.
Living Cell cleared to progress Parkinson's trial
26 November, 2013 by Dylan Bushell-EmblingThe data safety board monitoring the phase I/IIa trial of Living Cell Technologies' (ASX:LCT) NTCELL in Parkinson's will allow the remaining three patients to be implanted.
NSW takes lead in reducing barriers for clinical trials
26 November, 2013The NSW Office for Health and Medical Research (OHMR) is undertaking a project to reduce barriers to conducting clinical trials in the state and is conducting a survey to help reform the health and medical research pre-approvals process and improve the Research Ethics and Governance Information System (REGIS).
QRxPharma resubmits MoxDuo NDA in US again
26 November, 2013 by Dylan Bushell-EmblingQRxPharma (ASX:QRX) has filed for US approval for dual-opioid pain drug MoxDuo for the third time and, assuming approval, now aims for a launch in the second half of 2014.
Aussie stem cell firms jump on Japan fast-track
25 November, 2013 by Dylan Bushell-EmblingRegeneus (ASX:RGS) and Mesoblast (ASX:MSB) both plan to take advantage of a new expedited regulatory pathway for regenerative medicine products in Japan.
ResMed wins temporary German injunctions in patent suits
22 November, 2013 by Dylan Bushell-EmblingA German court has ordered a Taiwanese and a Chinese medical device manufacturer to stop selling some devices alleged to infringe ResMed (ASX:RMD) patents without a further court order.
TGA streamlines adverse event reporting
21 November, 2013AusBiotech has welcomed the TGA's announcement that it has introduced a streamlined way for sponsors to submit adverse event reports for medicines and vaccines, to ease the administrative burden of the 7000-8000 annual reports.
Mesoblast MPCs improve function in heart failure
20 November, 2013 by Dylan Bushell-EmblingDuring a recent trial, heart failure patients on assisted circular support demonstrated improved cardiac function when injected with Mesoblast (ASX:MSB) MPCs at time of LVAD implantation.
Avita facing 'first strike' on executive pay
20 November, 2013 by Dylan Bushell-EmblingAvita Medical's (ASX:AVH) two largest shareholders plan to vote against the company's remuneration report, with Bioscience Managers calling for the replacement of the chairman and CEO.
